Promoting the research progress of the CCA PDX model in immunotherapy will provide a theoretical basis for CCA clinical trials to evaluate the efficacy and safety of anti-PD-1, PD-L1 therapy and CCA immune-microenvironment therapy, and a promising preclinical research platform for CCA immunotherapy. The gene discussed is PDCD1; the disease is cholangiocarcinoma.